Lake Street Advisors Group LLC Buys 20,000 Shares of Hims & Hers Health, Inc. (NYSE:HIMS)

Lake Street Advisors Group LLC grew its stake in Hims & Hers Health, Inc. (NYSE:HIMS) by 42.2% during the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 67,366 shares of the company’s stock after purchasing an additional 20,000 shares during the quarter. Lake Street Advisors Group LLC’s holdings in Hims & Hers Health were worth $1,241,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of the stock. Carnegie Investment Counsel purchased a new stake in Hims & Hers Health in the third quarter worth $5,531,000. Diversify Advisory Services LLC bought a new position in Hims & Hers Health during the 1st quarter valued at approximately $701,000. Sei Investments Co. increased its position in Hims & Hers Health by 206.9% during the 1st quarter. Sei Investments Co. now owns 56,202 shares of the company’s stock valued at $869,000 after buying an additional 37,890 shares in the last quarter. Quantbot Technologies LP boosted its stake in Hims & Hers Health by 3,444.9% during the 1st quarter. Quantbot Technologies LP now owns 214,677 shares of the company’s stock valued at $3,321,000 after purchasing an additional 208,621 shares during the last quarter. Finally, Healthcare of Ontario Pension Plan Trust Fund boosted its stake in shares of Hims & Hers Health by 164.1% in the 2nd quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 528,142 shares of the company’s stock worth $10,663,000 after buying an additional 328,142 shares during the last quarter. Institutional investors own 63.52% of the company’s stock.

Insider Transactions at Hims & Hers Health

In other Hims & Hers Health news, insider Michael Chi sold 2,054 shares of the company’s stock in a transaction on Thursday, August 1st. The shares were sold at an average price of $22.00, for a total value of $45,188.00. Following the sale, the insider now directly owns 185,326 shares of the company’s stock, valued at approximately $4,077,172. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other news, insider Soleil Boughton sold 2,334 shares of the stock in a transaction on Tuesday, August 6th. The stock was sold at an average price of $17.30, for a total transaction of $40,378.20. Following the completion of the transaction, the insider now directly owns 164,475 shares in the company, valued at approximately $2,845,417.50. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Michael Chi sold 2,054 shares of the stock in a transaction dated Thursday, August 1st. The stock was sold at an average price of $22.00, for a total value of $45,188.00. Following the transaction, the insider now directly owns 185,326 shares in the company, valued at approximately $4,077,172. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 841,076 shares of company stock valued at $14,759,219. Corporate insiders own 17.71% of the company’s stock.

Hims & Hers Health Trading Up 1.0 %

HIMS opened at $21.73 on Friday. Hims & Hers Health, Inc. has a 12 month low of $5.65 and a 12 month high of $25.74. The stock has a 50-day moving average of $17.59 and a 200 day moving average of $17.83. The firm has a market cap of $4.67 billion, a P/E ratio of 271.66 and a beta of 1.06.

Hims & Hers Health (NYSE:HIMS) last announced its quarterly earnings results on Monday, August 5th. The company reported $0.06 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.04 by $0.02. The firm had revenue of $315.65 million during the quarter, compared to analyst estimates of $302.43 million. Hims & Hers Health had a return on equity of 5.25% and a net margin of 1.70%. Hims & Hers Health’s quarterly revenue was up 51.8% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.03) earnings per share. On average, research analysts forecast that Hims & Hers Health, Inc. will post 0.22 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on HIMS shares. Piper Sandler reaffirmed a “neutral” rating and issued a $18.00 target price on shares of Hims & Hers Health in a report on Tuesday, August 6th. Bank of America raised their target price on Hims & Hers Health from $23.00 to $25.00 and gave the stock a “buy” rating in a report on Monday, October 21st. Truist Financial raised their target price on Hims & Hers Health from $13.00 to $23.00 and gave the stock a “hold” rating in a report on Thursday, July 18th. Imperial Capital cut Hims & Hers Health from an “outperform” rating to an “in-line” rating in a report on Friday, August 9th. Finally, Needham & Company LLC started coverage on Hims & Hers Health in a report on Thursday, August 22nd. They issued a “buy” rating and a $24.00 target price on the stock. Eight investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat, Hims & Hers Health presently has a consensus rating of “Moderate Buy” and a consensus target price of $20.21.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.